# The Role of Propylthiouracil in the Management of Graves’ Disease in Adults

**April 18, 2009**  
**MEETING AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am – 8:30 am</td>
<td>Continental Breakfast</td>
</tr>
</tbody>
</table>
| 8:30 am – 8:45 am   | Introductions and Welcome  
Kenneth Burman, MD, ATA President, Washington Hospital Center  
Mary Parks, MD, FDA  
Donald Mattison, MD, NICHD, NIH; Anne Zajicek, MD, NICHD, NIH  
David S. Cooper, MD, Meeting Chair, Johns Hopkins University |
| 8:45 am – 9:30 am   | Antithyroid Drugs: Pharmacology, Clinical Use and Adverse Events in Adults  
David S. Cooper, MD, Johns Hopkins University |
| 9:30 am – 10:00 am  | Management of Thyrotoxicosis in Pregnancy  
Susan Mandel, MD, MPH, University of Pennsylvania |
| 10:00 am – 10:30 am | Antithyroid Drugs: Approval History and Labeling  
Naomi Lowy, MD, FDA |
| 10:30 am – 10:45 am | Break |
| 10:45 am – 11:15 am | Frequency of PTU and Methimazole Use: Outpatient Prescription Utilization Data  
Laura Governale, PharmD, MBA, FDA |
| 11:15 am – 11:45 am | PTU and Methimazole: Severe Liver Injury  
Joslyn Swann, PharmD, FDA |
| 11:45 am – 12:00 pm | Discussion |
| 12:00 pm – 1:00 pm | Lunch |
| 1:00 pm – 1:45 pm  | Methimazole Embryopathy and Possible Mechanisms of Teratogenesis  
Miyun Tsai-Turton, PhD, FDA |
| 1:45 pm – 2:30 pm  | Drug-Induced Liver Failure: Mechanisms  
John Senior, MD, FDA |
| 2:15 pm – 2:45 pm  | Break |
| 2:45 pm – 3:00 pm  | Drug-Induced Liver Failure: Epidemiology and Role of Monitoring  
Mark Avigan, MD, FDA |
| 3:00 pm – 3:30 pm  | Discussion |
| 3:30 pm           | Adjournment |